Finance

Lists
6919:TPE
Caliway Biopharmaceuticals Co Ltd
76,50 TWD
-0,91%
(-0,70) 1D
13-окт., 13:30:07 GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 6919...
Open
76,50 TWD
High
78,00 TWD
Low
75,10 TWD
Mkt. cap
119,13 млд
Avg. vol.
8,44 млн
Volume
4,40 млн
52-wk high
188,00 TWD
52-wk low
75,10 TWD
EPS
-0,17 TWD
Open
76,50 TWD
High
78,00 TWD
Low
75,10 TWD
Mkt. cap
119,13 млд
Avg. vol.
8,44 млн
Volume
4,40 млн
52-wk high
188,00 TWD
52-wk low
75,10 TWD
EPS
-0,17 TWD
News stories
From web sources and news partners
About Caliway Biopharmaceuticals Co Ltd
CEO-
Employees-
Founded2012
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 11-авг.
Fiscal period
Q2 2026
-0,14 TWD / 2,93 TWD
-104,78%miss
Revenue / Est. (TWD)
3,57 млн / 6,01 млд
-99,94%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
13,42 млн
12,41 млн
2,00 миң
3,57 млн
Cost of goods sold
4,09 млн
3,40 млн
1,00 миң
1,24 млн
Cost of revenue
4,09 млн
3,40 млн
1,00 миң
1,24 млн
Research and development expenses
244,51 млн
112,62 млн
212,41 млн
210,66 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-33,70 млн
17,06 млн
33,42 млн
54,75 млн
Operating expense
210,81 млн
129,69 млн
245,83 млн
265,41 млн
Total operating expenses
214,89 млн
133,09 млн
245,83 млн
266,65 млн
Operating income
-201,48 млн
-120,68 млн
-245,83 млн
-263,08 млн
Other non operating income
-280,00 миң
9,00 миң
-4,00 миң
-2,00 миң
EBT including unusual items
-7,73 млн
80,19 млн
-107,75 млн
-222,52 млн
EBT excluding unusual items
-7,73 млн
80,19 млн
-107,75 млн
-222,52 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7,73 млн
80,19 млн
-107,75 млн
-222,52 млн
Net profit margin
-57,62%
646,17%
-5 387 700,00%
-6 239,93%
Earnings per share
-0,01
0,05
-0,07
-0,14
Interest and investment income
59,73 млн
85,42 млн
78,51 млн
82,27 млн
Interest expense
-34,00 миң
-22,00 миң
-11,00 миң
-329,00 миң
Net interest expenses
59,70 млн
85,40 млн
78,50 млн
81,94 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-195,81 млн
-114,79 млн
-239,81 млн
-258,15 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору